

# Hazardous Drug (HD) Exposure Matters

8 million health care professionals a year are exposed to HDs in the work place<sup>1</sup>.

- Exposure side effects can range from temporary rashes to lifelong complications.



Mitomycin C is on the list of NIOSH-recognized HDs.

- MMC is cytotoxic, mutagenic, and carcinogenic with its hazards existing in all forms (as dry powder, in solution, and vapors from solution).



Health organizations have stressed the problem of HD exposure.


- Guidelines established by ASHP, NIOSH, U.S. Pharmacopeia, and others call for the use of Closed-System Transfer Devices (CSTDs) and personal protective equipment when handling HDs.

<sup>1</sup> Hazardous Drug Exposure in Health Care. Centers for Disease Control and Prevention Website. [www.cdc.gov/niosh/topics/hazdrug/](http://www.cdc.gov/niosh/topics/hazdrug/). Accessed September 18, 2015.



Mitosol<sup>®</sup> reduces the risk of MMC exposure.

- Mitosol<sup>®</sup> is FDA-approved MMC packaged with a CSTD and sponge tray designed to deliver MMC safely to the point of application during ophthalmic surgery.



## Mitosol® Facts

FDA-Approved for Ophthalmology	✓
Assured Sterility, Potency, Dosing	✓
AORN Compliant Sterile Transfer	✓
Closed Fluid Transfer	✓
Room Temp Storage	✓
cGMP Manufacturing Controls	✓
Detailed Instructions for Use	✓
NIOSH Compliant Disposal	✓
No "Black Box Warning"	✓
Shelf Life up to 24 months	✓



### INDICATION

Mitosol® (mitomycin for solution) 0.2 mg/vial Kit for Ophthalmic Use is an antimetabolite indicated as an adjunct to ab externo glaucoma surgery.

### Dosage & Administration

Mitosol® is intended for topical application to the surgical site of glaucoma filtration surgery and must be reconstituted prior to application. Sponges provided within the Mitosol® kit should be fully saturated with the entire reconstituted contents in a manner prescribed in the Instructions For Use. The sponge(s) should be applied to the treatment area for two minutes. Reconstituted Mitosol® should be used within one hour of reconstitution.

### IMPORTANT SAFETY INFORMATION

#### Contraindications

Mitosol® is contraindicated in patients that have demonstrated

a hypersensitivity to mitomycin and in women who are or may become pregnant during therapy.

#### Warnings & Precautions

Cell Death, mitomycin is cytotoxic. Use of mitomycin in concentrations higher than 0.2mg/mL or use for longer than 2 minutes may lead to unintended corneal and/or sclera damage including thinning or perforation. Direct contact with the corneal endothelium will result in cell death.

Hypotony. The use of mitomycin has been associated with an increased instance of post-operative hypotony.

Cataract Development. Use in phakic patients has been correlated to higher instance of lenticular change and cataract formation.

#### Adverse Events & Reactions

The most frequent adverse reactions to Mitosol® occur locally and include hypotony, hypotony maculopathy, blebitis, endophthalmitis, vascular reactions, corneal reactions, and cataract.

